Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

Advances in sequencing technology have made multigene testing, or “panel testing,” a practical option when looking for genetic variants that may be associated with a risk of breast cancer. In June

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels

Frontiers Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting

Current Oncology, Free Full-Text

An overview of genetic services delivery for hereditary breast cancer

The use of genomic sequencing panels to personalise cancer treatment is beneficial in only 5% of the patients in whom they are currently used - CNIO

Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk

Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. - Abstract - Europe PMC

Integrating a Polygenic Risk Score into a clinical setting would impact risk predictions in familial breast cancer

PDF) Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management

CHEK2 Carrier Modification with Polygenic Risk Score

Cancer carrier screening in the general population using whole‐genome sequencing - Chang - 2023 - Cancer Medicine - Wiley Online Library